We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
VIZO-PF BIMATOPROST (AFT Pharmaceuticals Pty Ltd)
Product name
VIZO-PF BIMATOPROST
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
119 working days (255)
Active ingredients
bimatoprost
Registration type
New generic medicine
Indication
VIZO-PF BIMATOPROST (eye drops) is indicated for the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta-blockers.